HCV/HIV Co-infection
HCV and HIV co-infection is correlated with accelerated hepatic fibrosis advancement and high rates of liver deterioration and death when compared to HCV monoinfection. Among HIV-infected patients, liver dysfunction is a leading cause of non-AIDS-related mortality. Hepatitis C virus is found in about one-third of HIV patients. Hepatitis C virus can be transmitted in the same way that HIV and Hepatitis B do. HIV not only hastens the beginning of liver damage, but it also hastens the onset of liver infection. Patients who are co-infected with HCV and HIV must work closely with their doctors to monitor and treat both illnesses.
Related Conference of HCV/HIV Co-infection
October 24-25, 2024
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
HCV/HIV Co-infection Conference Speakers
Recommended Sessions
- Advancement in New Drug Discovery for Treatment of Hepatitis
- Alternative Medicine Use for Liver Diseases
- Critical care and Hepatology Nursing
- Gastrointestinal Endoscopy
- HCV/HIV Co-infection
- Hepatitis : Care and Cure
- Hepatitis and its Types
- Hepatitis Vaccination
- Liver Cancer and Hepatocellular Carcinoma
- Liver Diseases Diagnosis
- Liver Inflammation and Immunology
- Liver Transplantation and Surgery
- Molecular Biology of Hepatitis A, B, C, D and E Viruses
- Pancreatic Diseases
- Pediatric Gastroenterology, Hepatology and Nutrition
- Recent Advances in the Viral Hepatitis C Treatment
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)